• AASLD: Can low liver fat be bad for your heart? Visceral Fat & Heart Disease - (11/24/20)
   
  
• AASLD: Breastfeeding Linked to Lower Chance of Severe Fibrosis in US Women With NAFLD - Mark Mascolini - (11/24/20)
   
  
• ViiV Healthcare announces results of the PROgress study demonstrating that the inclusion of patient reported outcomes into clinical practice can improve HIV care - (11/18/20)
   
  
• ViiV Healthcare receives FDA Breakthrough Therapy Designation for investigational, long-acting cabotegravir for HIV prevention - (11/18/20)
   
  
• Merck Advances Phase 3 Trial to Evaluate Investigational Islatravir as Once-Monthly Oral PrEP for Women at High Risk for Acquiring HIV-1 - (11/18/20)
   
  
• AASLD: Cirrhosis Regression is Associated with Improved Clinical Outcomes in Patients with Nonalcoholic Steatohepatitis - (11/17/20)
   
  
• AASLD: Sugary Drinks, High Trans Fats Lead Dietary Risks for Death With NAFLD - Mark Mascolini (11/17/20)
   
  
• AASLD: The Lipidomics of HIV-related NAFLD - (11/17/20)
   
  
• AASLD: Dietary Risks for Liver Related Morality Among Nonalcoholic Fatty Liver Disease (NAFLD) - (11/17/20)
   
  
• AASLD: Treatment with Growth Hormone-Releasing Hormone Analog ReducesVEGFA, TGFβ1, and CSF1: Mechanisms of Tesamorelin Effect in Nonalcoholic Fatty Liver Disease - (11/17/20)
   
  
• AASLD: Country and WHO Regional Trends for Hepatitis C Virus (HCV) Mortality, 1990-2019: An Analysis of the Global Burden of Disease (GBD) Study - (11/17/20)
   
  
• AASLD: Statins Tied to Lower HCC Risk in HBV Group Without Cirrhosis - Mark Mascolini (11/17/20)
   
  
• ViiV Healthcare announces CHMP positive opinion for the first-ever dispersible-tablet formulation of dolutegravir, Tivicay, a treatment for children living with HIV in Europe - (11/13/20)
   
  
• Treatment Is More Than Prevention: Perceived Personal and Social Benefits of Undetectable = Untransmittable Messaging Among Sexual Minority Men Living with HIV - (11/12/20)
   
  
• Statement-NIH Study Finds Long-Acting Injectable Drug Prevents HIV Acquisition in Cisgender Women - (11/09/20)
   
  
• ViiV Healthcare announces investigational injectable cabotegravir is superior to oral standard of care for HIV prevention in women - (11/09/20)
   
  
More HIV Articles...
 

• UNAIDS Press release - COVID-19 could affect the availability and cost of antiretroviral medicines, but the risks can be mitigated - (06/25/20)
   
  
• UCLA receives nearly $14 million from NIH to investigate gene therapy to combat HIV - (06/24/20)
   
  
More News Updates Articles...
 

• HCV & HCV/HIV Coinfection Micro-Elimination Grants: funding for 30+ projects - -
   
  
• EASL: Summary from EASL 2018 for Hepatitis C (HCV) HCV in 2018: Success stories and remaining challenges? - Prof. Dr. J.K. Rockstroh Department of Medicine I University of Bonn Sigmund-Freud-Str. 25 53105 Bonn Germany-
   
  
• EASL: HCV Micro-Elimination Funding Grants Available
   
  
• Ledipasvir plus sofosbuvir in pregnant women with hepatitis C virus infection: a phase 1 pharmacokinetic study - (11/24/20)
   
  
• Drug Interactions between DAAs & Illicit/recreational drugs or drugs of abuse - from the EASL Guidelines - (11/24/20)
   
  
• AASLD: COST-EFFECTIVENESS OF ANTENATAL RESCREENING AMONG PREGNANT WOMEN FOR HEPATITIS C IN THE UNITED STATES (11/20/20)
   
  
More Hep C Articles...
 

• AASLD: Impact of Pretreatment Plasma HBV DNA Levels on the Rate of ALT Normalization During Antiviral Therapy With Tenofovir Alafenamide or Tenofovir Disoproxil Fumarate for Chronic Hepatitis B - (11/23/20)
   
  
• AASLD: Amino Acid Substitutions in the Inhibitor Binding Pocket of HBV Core Protein Confer Differential Changes in Susceptibility to Three Generations of HBV Core Inhibitors - (11/23/20)
   
  
• AASLD: Persistently detectable serum HBV DNA and pgRNA is associated with subsequent hepatocellular carcinoma development in chronic hepatitis B patients receiving chronic NRTI treatment - (11/23/20)
   
  
• AASLD: Analysis of the longer-term safety profile of the hepatitis B virus core inhibitor ABI-H0731 in an open-label extension study - (11/23/20)
   
  
• AASLD: HBV RNAi INHIBITOR RG6346 IN PHASE 1b-2a TRIAL WAS SAFE, WELL-TOLERATED, AND RESULTED IN SUBSTANTIAL AND DURABLE REDUCTIONS IN SERUM HBsAg LEVELS - (11/23/20)
   
  
• AASLD: Short-term therapy with GSK3228836 in chronic hepatitis B (CHB) patients results in reductions in HBcrAg and HBV RNA: Phase 2a, randomized, double-blind, placebo-controlled study - (11/23/20)
   
  
• AASLD: Changes in Viral Antigens are More Strongly Associated with HBV pgRNA than HBV DNA in Studies of Vebicorvir and NrtI in Treatment-naïve Patients with Chronic HBV Infection - (11/23/20)
   
  
• AASLD: FUNCTIONAL CURE OF CHRONIC HEPATITIS B IS ASSOCIATED WITH CO-OCCURRENCE OF HBsAg/anti-HBsIMMUNE COMPLEXES WITH ALT FLARES, AND SEROCONVERSION TO NEUTRALISING anti-HBs - (11/23/20)
   
  
• AASLD: Impact of HBV on Patients - A Qualitative Literature Review to Build a Patient-Focused Outcome Measurement Strategy for Chronic Hepatitis B - (11/23/20)
   
  
• AASLD: Timing of Administration of Anti-PD-1 is Important to Increase HBV-specific Immune Responses in AAV-HBV Mice - (11/23/20)
   
  
More Hep B Articles...
 

List not necessarily listed here in order of date being held.